Vaxart (VXRT) Fireside chat summary

Introduction and agenda

• Management recapped key developments, including partnerships, clinical milestones, and cost management as priorities moving into 2026.

• The agenda included a Q&A session with stockholders, focusing on clinical progress, partnerships, and financial strategy.

Background and experience of the speaker

• The panel included the CEO, Chief Scientific Officer, Chief Medical Officer, CFO, and General Counsel, each providing insights into their respective areas.

Current industry trends

• The vaccine funding environment remains in flux domestically, with increased scrutiny on mRNA vaccines and shifting public sentiment.

• Global demand for effective, thermostable, and easy-to-administer vaccines is growing, with major international commitments for immunization funding.